The pandemic has sparked greater interest among patients in Europe’s role in drug manufacturing. New research reveals that seven in ten patients now want to know where their drugs are made, as the pandemic has exposed the weaknesses of the growing concentration of production of essential drugs abroad.
The study found that the vast majority (84%) of patients want their government to support investments in pharmaceutical manufacturing in their region in order to avoid overdependence on countries outside of the country. Europe.
The study surveyed thousands of European patients who depend on regular medicines for chronic illnesses and found that 7 in 10 (71%) are interested in knowing that Europe remains as competitive as other regions.
The results underscore the need to rebalance the global pharmaceutical value chain to ensure that every region of the world has reliable access to life-saving medicines.
It comes as the COVID-19 pandemic has highlighted problems with global supply chains caused by the manufacturing of active pharmaceutical ingredients bundled in Asia. While Europe remains strong in the production of finished medicines, it has lost its leading position in the manufacture of active pharmaceutical ingredients in the off-patent generic sector – especially for essential medicines like paracetamol – thus opening up new possibilities. strategic vulnerabilities.
The Teva Pharmaceuticals study solicited the opinions of 3,000 patients over the age of 25 in France, Germany, the Netherlands, Spain, Croatia and the Czech Republic. All of the participants suffered from one or more chronic illnesses, including Alzheimer’s disease, arthritis, asthma, cancer, cardiovascular disease, COPD, depression, diabetes, heart disease and migraine, requiring regular medication.
Richard Daniell, Executive Vice President of Teva in Europe, said: âThe pandemic shock is acting as a wake-up call that the growing imbalance in the global pharmaceutical value chain cannot be sustained.
Patients now really care about where their drugs are made. Just as âfood milesâ have become a major concern of consumers in recent years, patients now want to know more about âmedicine milesâ in terms of the treatments they are taking.
Europe’s excessive and unhealthy dependence on manufacturing active pharmaceutical ingredients abroad has been highlighted by the closure of factories and borders. But nationalist approaches do not work in an area as strongly connected and interdependent as the supply of modern medicine. Europe must adjust its policies to new economic and technological realities, while developing its competitiveness and its geopolitical position by remaining open and attracting investment.
âTeva supports 200 million patients every day, keeping the European medicine cabinet in stock, as one of the largest suppliers to European healthcare systems. Today, we manufacture 95% of Teva medicines in Europe, supported by our global supply chain. And we are investing nearly a billion euros in manufacturing facilities across Europe. What is illuminating about this research is that patients are becoming aware of these issues and are demanding changes.
âThe race for the cheapest generics must end and the rather inflexible and outdated European regulatory regime must be modernized to keep Europe in the race to attract pharmaceutical investments to produce critical APIs and generic drugs.
âWith the needs of patients at its heart, a new balance should also improve Europe’s resilience and make a significant economic contribution to the region. There is an opportunity to seize this watershed moment and build a better ecosystem in which a stronger pharmaceutical manufacturing presence in Europe can complement the rest of the global supply chain. “
Research shows that European patients see such commitments as vital for a sustainable future.
Almost three-quarters (73%) of people believe that the pharmaceutical industry is strategically important for Europe as we emerge from the pandemic because it can ensure the stability and reliability of drug supplies.
Almost two-thirds (61%) believe that drug manufacturing in the region is important to protect European health systems, and roughly the same number (59%) see it as crucial to ensuring autonomy and sovereignty of Europe on critical drugs.
The study found that 85% of patients see the pharmaceutical sector as critical to boosting economic recovery as we emerge from the depths of the pandemic.
People cited job creation and supporting the local economy as the main benefit for promoting drug manufacturing in Europe (57%), followed closely by the desire for better access to essential drugs. and reduce dependence on overseas sourcing (56%).
In addition, over 70% of European patients want Europe to remain as competitive as other regions and expect their government to take action to support this.
The environment was a major concern among patients with 65% of them demanding that their drugs be manufactured in an environmentally friendly way.
In addition, more than half (55%) of patients see the benefits of medicines manufactured in Europe linked to the potential environmental impact linked to reduced transport. And more than a third (35%) of people believe that Europe guarantees greener production and compliance with environmental regulations than manufacturing overseas.
About Teva and its impact in Europe
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) have been developing and producing drugs to improve people’s lives for 120 years. We are a global leader in generic and specialty drugs with a portfolio of more than 3,500 products in almost all therapeutic areas.
About 200 million people around the world take a Teva medicine every day and are served by one of the pharmaceutical industry’s largest and most complex supply chains. In addition to our established presence in generics, we have significant innovative research and operations activities supporting our growing portfolio of specialty and biopharmaceutical products. Teva operated 32 manufacturing and research and development facilities across Europe in 2020.
In Europe, local purchases and Teva’s payroll in nine key markets supported nearly 105,000 jobs, contributed $ 29.5 billion (â¬ 25.8 billion) to economic output and generated 5.6 billion dollars (4.9 billion euros) in labor income. Generic drugs from Teva saved healthcare systems in nine European countries $ 9.6 billion (â¬ 8.4 billion) in 2020. Learn more about Teva and its Economic impact.